在一项新的研究中，来自丹麦国家教学研究医院和哥本哈根大学的研究人员基于抗体-药物偶联物（antibody-drug conjugate, ADC）技术，在开发胰腺癌治疗方法方面取得了重大进展。相关研究结果近期发表在 Science Advances ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

点击蓝字关注我们【导读】重新编程肿瘤免疫微环境（TIM）在促进免疫“冷”肿瘤向“热”炎症肿瘤的逆转方面发挥着重要作用。提高药物靶向性、阻断免疫检查点以及促进免疫细胞的活化对于重新编程 TIM ...

综上所述，2024 ASH 年会展示的这些 BCMA 靶向疗法的临床试验结果令人振奋，为 MM 患者带来了新的希望。这些研究成果不仅进一步证实了 BCMA 靶向疗法在 MM 治疗中的有效性，还为不同阶段 MM ...

点击蓝字关注我们【导读】肿瘤相关中性粒细胞（TANs）在肿瘤微环境（TME）中积极与抗体药物共轭物（ADCs）相互作用，但它们对ADC治疗反应的详细机制仍有待全面阐明。在这项研究中，团队探讨了ICAM1靶向ADC如何影响宫颈癌临床前模型中的TAN动态 ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

Akeso is dedicated to transforming the global oncology treatment landscape by establishing new standards of care for cancer patients worldwide. A key element of this mission is the company's "IO 2.0 + ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) ...